Merck (MRK) EV to EBITDA (2009 - 2026)
Merck (MRK) EV to EBITDA (2009 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EV to EBITDA |
| 1 |
Gsk |
96,436,181.12 Bn |
96,436,176.16 Bn |
7.76 Bn |
8.97 Mn |
| 2 |
Eli Lilly |
1,017.30 Bn |
1,012.01 Bn |
16.22 Bn |
30.26 |
| 3 |
Johnson & Johnson |
579.61 Bn |
557.55 Bn |
15.96 Bn |
13.90 |
| 4 |
AbbVie |
402.30 Bn |
392.96 Bn |
10.78 Bn |
25.63 |
| 5 |
Merck |
294.24 Bn |
288.59 Bn |
12.09 Bn |
-52.21 |
| 6 |
Amgen |
191.82 Bn |
179.78 Bn |
5.87 Bn |
17.01 |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
14.29 |
| 8 |
Pfizer |
149.05 Bn |
136.28 Bn |
-1.21 Bn |
-7.69 |
| 9 |
Bristol Myers Squibb |
116.33 Bn |
105.88 Bn |
8.07 Bn |
14.44 |
| 10 |
Novartis Ag |
112.59 Bn |
111.90 Bn |
- |
6.37 |
| Date | Value |
|---|
| Jun 12, 2026 |
-52.21 |
| Jun 11, 2026 |
-53.03 |
| Jun 10, 2026 |
-52.20 |
| Jun 9, 2026 |
-52.44 |
| Jun 8, 2026 |
-52.36 |
| Jun 5, 2026 |
-52.99 |
| Jun 4, 2026 |
-52.76 |
| Jun 3, 2026 |
-50.27 |
| Jun 2, 2026 |
-51.00 |
| Jun 1, 2026 |
-50.53 |
| May 29, 2026 |
-52.07 |
| May 28, 2026 |
-52.59 |
| May 27, 2026 |
-52.75 |
| May 26, 2026 |
-52.84 |
| May 22, 2026 |
-53.72 |
| May 21, 2026 |
-50.79 |
| May 20, 2026 |
-49.51 |
| May 19, 2026 |
-50.09 |
| May 18, 2026 |
-49.37 |
| May 15, 2026 |
-48.78 |
